Total
|
n = 494
|
n = 168
|
n = 662
|
Treatment duration [median (IQR)]
|
Start to completion (months)
|
19.0 (9.8–20.0)
|
20.0 (9.7–21.3)
|
19.0 (9.7–20.0)
|
Inpatient regimen (days)
|
25 (16–34)
|
33 (19–42)
|
28 (16–37)
|
Smear conversion after 2 months
|
n = 454
|
n = 132
|
n = 586
|
Yes
|
418 (92.1%)
|
85 (64.4%)
|
503 (85.8%)
|
No
|
36 (7.9%)
|
47 (35.6%)
|
83 (14.2%)
|
Not reported
|
40
|
36
|
76
|
Smear conversion after 4 months
|
n = 421
|
n = 116
|
n = 537
|
Yes
|
409 (97.1%)
|
110 (94.8%)
|
519 (96.6%)
|
No
|
12 (2.9%)
|
6 (5.2%)
|
18 (3.4%)
|
Not reported
|
73
|
52
|
125
|
Culture conversion after 2 months
|
n = 448
|
n = 105
|
n = 553
|
Yes
|
405 (90.4%)
|
10 (9.5%)
|
415 (75.0%)
|
No
|
43 (9.6%)
|
95 (90.5%)
|
138 (25.0%)
|
Not reported
|
46
|
63
|
109
|
Culture conversion after 4 months
|
n = 420
|
n = 108
|
n = 528
|
Yes
|
402 (95.7%)
|
86 (79.6%)
|
488 (92.4%)
|
No
|
18 (4.3%)
|
22 (20.4%)
|
40 (7.6%)
|
Not reported
|
74
|
60
|
134
|
Side effects during treatment
|
At least one inpatient side effect reported
|
n = 308
|
n = 144
|
n = 452
|
Yes
|
23 (7.5%)
|
16 (11.1%)
|
39 (8.6%)
|
No
|
285 (92.5%)
|
128 (88.9%)
|
413 (91.4%)
|
Not reported
|
186
|
24
|
210
|
At least one outpatient side effect reported
|
n = 447
|
n = 125
|
n = 572
|
Yes
|
75 (16.8%)
|
32 (25.6%)
|
107 (18.7%)
|
No
|
372 (83.2%)
|
93 (74.4%)
|
465 (81.3%)
|
Not reported
|
47
|
43
|
90
|
Outpatient side effects reporteda
|
n = 195
|
n = 52
|
n = 247
|
Blood disorder
|
6 (3.1%)
|
0 (0%)
|
6 (2.4%)
|
Bowel pain
|
3 (1.5%)
|
2 (3.8%)
|
5 (2.0%)
|
Hearing loss
|
9 (4.6%)
|
3 (5.8%)
|
12 (4.9%)
|
Hepatotoxicity
|
35 (17.9%)
|
0 (0%)
|
35 (14.2%)
|
High blood sugar
|
10 (5.1%)
|
0 (0%)
|
10 (4.0%)
|
High uric acid
|
42 (21.5%)
|
0 (0%)
|
42 (17.0%)
|
Hypokalemia
|
15 (7.7%)
|
0 (0%)
|
15 (6.1%)
|
Joint pain
|
19 (9.7%)
|
16 (30.8%)
|
35 (14.2%)
|
Loss of appetite
|
11 (5.6%)
|
0 (0%)
|
11 (4.5%)
|
Nephrotoxicity
|
17 (8.7%)
|
0 (0%)
|
17 (6.9%)
|
Neurotoxicity
|
7 (3.6%)
|
1 (1.9%)
|
8 (3.2%)
|
Nausea
|
0 (0%)
|
23 (44.2%)
|
23 (9.3%)
|
Vision loss
|
7 (3.6%)
|
2 (3.8%)
|
9 (3.6%)
|
Vertigo
|
14 (7.2%)
|
5 (9.6%)
|
19 (7.7%)
|
Not reported
|
299
|
116
|
415
|